Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Investing Activities (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Cash from Investing Activities data on record, last reported at $29.5 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 54.65% year-over-year to $29.5 million; the TTM value through Dec 2025 reached $14.0 million, down 81.44%, while the annual FY2025 figure was $14.0 million, 81.44% down from the prior year.
  • Cash from Investing Activities reached $29.5 million in Q4 2025 per AMLX's latest filing, up from $5.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $123.2 million in Q2 2023 and bottomed at -$228.2 million in Q4 2022.
  • Average Cash from Investing Activities over 5 years is -$5.5 million, with a median of $4.5 million recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: crashed 709264.29% in 2022, then surged 2661.59% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at $2.8 million in 2021, then tumbled by 8208.74% to -$228.2 million in 2022, then surged by 109.17% to $20.9 million in 2023, then soared by 210.54% to $65.0 million in 2024, then plummeted by 54.65% to $29.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $29.5 million in Q4 2025, $5.2 million in Q3 2025, and $23.0 million in Q2 2025.